<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447628</url>
  </required_header>
  <id_info>
    <org_study_id>CRO1811</org_study_id>
    <nct_id>NCT01447628</nct_id>
  </id_info>
  <brief_title>IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients</brief_title>
  <official_title>What is the Effect of Intravenous Iron Supplementation on Cardiopulmonary Haemodynamics, Exercise Capacity and Quality of Life in Patients With IPAH and Iron Deficiency?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fu Wai Hospital, Beijing, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish whether intravenous iron replacement has clinical benefit in&#xD;
      idiopathic pulmonary arterial hypertension.&#xD;
&#xD;
      A 24-week double-blind, randomised, placebo-controlled, crossover study will investigate&#xD;
      whether a single dose of 1g of Ferinject® or CosmoFer improves cardiopulmonary haemodynamics,&#xD;
      exercise capacity and quality of life and is well-tolerated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IV iron formulation used in Europe - Ferinject IV iron formulation used in China - CosmoFer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in resting pulmonary vascular resistance (PVR)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>To be measured by cardiac catheterisation in wood units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Exercise Capacity - Endurance</measure>
    <time_frame>12 Weeks post study treatment</time_frame>
    <description>Endurance time at the end of the endurance bicycle cardiopulmonary exercise testing at 80% peak work rate determined from the incremental exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in exercise capacity - Incremental</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Incremental bicycle cardiopulmonary exercise testing - peak VO2 (ml/min/kg), VO2 at metabolic threshold, VE/VCO2 slope, VO2/WR slope and O2 pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron indices</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Iron indices - serum iron, transferrin saturations, ferritin, soluble transferrin receptor, RDW, EPO, and UIBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Cardiac MRI - right ventricular volumes, mass, ejection fraction, stroke volume and diastolic function (reported in mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance and Borg dyspnoea scale</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>6 minute walk distance (meters) and Borg dyspnoea scale (from 1-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO functional class</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>WHO Functional Class (I-IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Change in NT-proBNP (fmol/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assess by questionnaire</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Quality of life (CAMPHOR questionnaire) and the self-reported Patient Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - In terms of reported adverse events</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Safety - the number, occurrence and frequency of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in gas exchange at 3 minutes</measure>
    <time_frame>12 weeks post study treatment</time_frame>
    <description>Gas exchange at 3 minutes from an endurance exercise test at 80% peak work rate determined from the incremental exercise test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Ferinject or CosmoFer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV iron formulation used in Europe - Ferinject - given over 15 minutes&#xD;
IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intravenous, no active drug</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject or CosmoFer</intervention_name>
    <description>Intravenous, 1000 mg iron</description>
    <arm_group_label>Ferinject or CosmoFer</arm_group_label>
    <other_name>Intravenous Iron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Males or females aged between 16-75 years old&#xD;
&#xD;
          -  PAH which is idiopathic, heritable or associated with anorexigens.&#xD;
&#xD;
          -  Iron deficiency (TfR levels &gt; 28.1 nmol/l, where sTfR analysis is available, Ferritin&#xD;
             &lt; 37 ug/l; transferrin saturations &lt; 16.4%; iron &lt; 10.3 umol/l)&#xD;
&#xD;
          -  Documented diagnosis of PAH by right heart catheterisation performed at any time prior&#xD;
             to Screening showing: resting mean pulmonary artery pressure &gt;25mmHg, pulmonary&#xD;
             capillary wedge pressure =/&lt; 15 mm Hg and normal or reduced cardiac output;&#xD;
&#xD;
          -  6 minute walking distance greater than 50m at entry;&#xD;
&#xD;
          -  Stable on an unchanged PAH therapeutic regime (any combination of endothelin receptor&#xD;
             antagonist, phosphodiesterase inhibitor or prostacyclin analogue) for at least 1&#xD;
             month.&#xD;
&#xD;
          -  Able to provide written informed consent prior to any study-mandated procedures&#xD;
&#xD;
          -  Female subjects of child-bearing potential are eligible to participate if they agree&#xD;
             to use one of the following contraception methods:&#xD;
&#xD;
          -  Abstinence&#xD;
&#xD;
          -  Contraceptive methods with a failure rate of &lt; 1%:&#xD;
&#xD;
          -  Oral contraceptive, either combined or progestogen alone;&#xD;
&#xD;
          -  Injectable progestogen;&#xD;
&#xD;
          -  Implants of levonorgestrel;&#xD;
&#xD;
          -  Estrogenic vaginal ring;&#xD;
&#xD;
          -  Percutaneous contraceptive patches;&#xD;
&#xD;
          -  Intrauterine device (IUD) or intrauterine system (IUS) that meets the &lt;1% failure rate&#xD;
             as stated in the product label;&#xD;
&#xD;
          -  Male partner(s) sterilization (vasectomy with documentation of azoospermia) prior to&#xD;
             the female subject's entry into the study;&#xD;
&#xD;
          -  Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps)&#xD;
             plus vaginal spermicidal agent (foam/gel/film/cream/suppository).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Unable to provide informed consent.&#xD;
&#xD;
          -  Clinically-significant renal disease (Creatinine clearance &lt; 30 ml/min per 1.73 m2&#xD;
             calculated from CKD-Epi http://www.qxmed.com/renal/Calculate-CKD-EPI-GFR.php) or liver&#xD;
             disease (including serum transaminases &gt; 3 times upper limit of normal).&#xD;
&#xD;
          -  Haemoglobin concentration &lt;10 g/dl.&#xD;
&#xD;
          -  Patients will be excluded if any single parameter (iron, ferritin or transferrin&#xD;
             saturation) exceeds 1x upper limit of normal (ULN) in the local lab reference range.&#xD;
&#xD;
          -  Patients with moderate to severe hypophosphatemia as defined as &lt;0.65mmol/L&#xD;
&#xD;
          -  Known to have haemoglobinopathy e.g. sickle cell disease, thalassaemia.&#xD;
&#xD;
          -  Admission to hospital related to PAH or change in PAH therapy within 1 month prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Evidence of left ventricular disease or significant lung disease on high-resolution CT&#xD;
             scanning or lung function as judged by the investigator&#xD;
&#xD;
          -  Acute or chronic infection or inflammation.&#xD;
&#xD;
          -  Significant uncontrolled asthma as judged by the investigator, eczema or atopic&#xD;
             allergies.&#xD;
&#xD;
          -  Females who are lactating or pregnant.&#xD;
&#xD;
          -  Individuals known to have HIV, Hepatitis B or C or Creutzfeld-Jakob disease.&#xD;
&#xD;
          -  Known hypersensitivity to Ferinject® or any of its excipients.&#xD;
&#xD;
          -  Evidence of disturbances in utilisation of iron.&#xD;
&#xD;
          -  Significant blood loss (e.g. GI bleed) within the last 3 months or history of&#xD;
             menorrhagia.&#xD;
&#xD;
          -  Unable to perform a Cardiopulmonary Exercise Test i.e. due to syncope or&#xD;
             musculoskeletal factors.&#xD;
&#xD;
          -  Patients who have received an investigational medicinal product within 30 days of&#xD;
             entering the baseline visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke Howard, DPhil, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig University</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital, Imperial College NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic pulmonary arterial hypertension (IPAH)</keyword>
  <keyword>Iron deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01447628/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01447628/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>September 24, 2019</submitted>
    <returned>October 18, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

